Novo Nordisk subpoenaed by US Attorney

25 October 2014
medical_legal_law_big

Shares of Danish diabetes care giant Novo Nordisk (NOV: N) fell as much as 2.3% before recovering some ground to close 0.9% lower at 267.10 Danish kroner on Friday, after the company revealed it had been served with a subpoena by the office of the US Attorney for the District of Massachusetts.

The subpoena is requesting documents regarding potential manufacturing issues within certain production units located in Kalundborg, Denmark. Novo Nordisk said it is cooperating fully with the US Attorney in this investigation.

“At this time, Novo Nordisk cannot determine or predict the outcome of this matter or assess the consequences thereof. In addition, the company cannot predict how long the investigation will take or when it will be able to provide additional information,” the company stated.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical